Over the last decade, the number of cell and gene therapy clinical trials has more than tripled. In this article, several ...

This article examines some of the cell-based approaches that researchers are using to study acquired drug resistance and the ...

Neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are medical conditions characterized by the progressive degradation ...

A research team led by Professor Lee Hyun-ji (co-first authors Kim Sang-hoon, Kim Ji-eun, Joo Sung-jin, PhD student at Korea ...

Aperture will advance APRTX-001 as a potential treatment for ALS and frontotemporal dementia, with possible expansion for use ...

A hidden four-layer structure in the brain’s key memory hub has been revealed, reshaping how scientists understand learning ...

Groundbreaking brain atlases reveal dynamic neuron and glia development across species, transforming static maps into a ...

Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced changes to its Board of Directors, including the departure of two directors and the appointment of a new ...

A Penn-led research team has uncovered how hydralazine, one of the oldest blood pressure medications and a standard treatment for preeclampsia, functions at the molecular level.

Aging fundamentally transforms the human genome through accumulative epigenetic modifications—including DNA methylation, ...

Generative artificial intelligence is moving from the margins of pharma into the center of how new medicines are imagined, ...

Lung cancer remains the most frequently diagnosed malignancy and the leading cause of cancer tumour-related mortality ...